We are
biotech
innovators

We are a global group of biotech innovators, rooted in Belgium, driven by one purpose: To transform how biotech drugs are made so everyone, everywhere, can get them.

Through cutting-edge bioprocessing and technology, we create transformative processes and platforms across drug discovery, development, and delivery.

Our Focus?

Driving accessibility, affordability, and sustainability, we eliminate barriers for drug developers. Collaborating with the biotech and pharmaceutical industries, we pave the way for new vaccines and therapies targeting cancer, infectious diseases, and animal health.

With support from world-leading and mission-aligned stakeholders like the Bill & Melinda Gates Foundation, the European Investment Bank, and the Global Health Investment Corporation, we’re poised to make a difference on a global scale.

gates foundation

gates foundation

gates foundation

Innovation at Univercells

Sustainability

At Univercells, sustainability isn’t an afterthought; it’s woven into our operations. Sustainability is a balance between maximizing societal impact, ensuring financial sustainability, and aligning with our Environmental, Social, and Governance commitments.

Download our 2023 Impact Report

People

Our team represents the markets we want to serve with scientists, experts and entrepreneurs from all over the world. With extensive experience and deep expertise in tech and bioprocesses, we have a track record of consistent customer success.

hugues-bultot img

Hugues Bultot

Chief Executive Officer

hugues-bultot img

José Castillo

Chief Technology Officer

hugues-bultot img

Kate Antrobus

Chief Business Officer

hugues-bultot img

Vincent Vanderborght

Chief Financial Officer

hugues-bultot img

David Louvet

Chief Operating & HR Officer

hugues-bultot img

Tim Carlson

President

hugues-bultot img

Hala Audi

Chief Alliance Officer

“The innovative team we have built to support Univercells’ purpose is the real source of the value we create.”

Vincent Vanderborght, CFO

Join Us

Stakeholders

As scientists and entrepreneurs, we generate value by bringing market-driven innovation to life.

We embrace challenges. Where others see roadblocks, we find a way around them to create unique businesses. Our shareholders understand that, with a strong dynamic of long-time supporters welcoming new investors throughout various equity rounds.

Our diverse pool of stakeholders has played a crucial role in our successes, challenging us to go faster and further.

Belgian Sovereign and Regional Funds

Selected Funders

Other Lead Investors

Hugues Bultot

Chief Executive Officer

Hugues has a proven entrepreneurial track record of success as CEO of MaSTherCell, Artelis, and Kitozyme. He brings over two decades of leadership in Life Sciences and Biotechnology. Hugues is also the Vice-President SME of BioWin, the Health Cluster of Wallonia, Belgium. He holds degrees from UCL and Solvay Business School, along with certifications from ICHEC and MIT Sloan School of Management.

José Castillo

Chief Technology Officer

José is recognized as a serial entrepreneur and prolific innovator in the biopharmaceutical industry. With a strong track record in innovative processes and design to make biotech drugs more affordable and accessible, he played a crucial role in creating the Nevoline platform.

José is also CEO of our platform technologies business, Quantoom Biosciences.

Kate Antrobus

Chief Business Officer

Kate champions business initiatives that consider global health and access as key drivers of sustainable value creation. With a background in leading healthcare initiatives that span drug development, international development and innovative finance Kate has advised diverse clients including the Bill & Melinda Gates Foundation and sovereign states. She holds degrees from Oxford, Columbia and the London School of Economics.

Vincent Vanderborght

Chief Financial Officer

Vincent brings over two decades of financial and supply chain leadership experience, notably with Pfizer and Zoetis. He is also a visiting professor at the Louvain School of Management. Vincent holds a Master’s in business engineering from UCL in Belgium.

David Louvet

Chief Operating & HR Officer

David oversees Univercell’s human resources, curating a team of passionate biotech innovators. With two decades of experience spanning human resources, operations, and project management, David drives performance improvement in a dynamic environment. Prior roles include stints at Pall LifeSciences, BNP Paribas Fortis, Allianz, Cofidis Belgium, and Deloitte. David holds a Master’s in human resources from Vlerick Business School in Belgium.

David is also CEO of our regulatory affairs support business, RLM Consulting.

Tim Carlson

President

Tim is a seasoned financial leader with extensive experience as CFO in listed companies and large scale industry (semiconductors, life sciences technologies), bringing strategic expertise in treasury, financial planning, and risk management. His career includes strategic roles at Campbell Soup Company and Ernst & Young. Tim holds a Bachelor of Science in Economics from the University of Pennsylvania, Wharton School of Business, and is a licensed CPA.

Hala Audi

Chief Alliance Officer

Hala has 20 years of international experience. She led complex projects across the public, private, and charitable sectors that focused on innovation in pharma economics, antimicrobial resistance and pandemic preparedness. Hala also gained a deep understanding of the infrastructure and construction sectors during her legal and governmental career. Hala is a law graduate from Université Paris-II Assas and Columbia University and later gained her Masters in Public Administration by studying at Harvard Kennedy School and the LSE in London.

Hala is also CEO of our international project management business, Unizima.